Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.
JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $250 to $260.
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...
AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfol...
-Reuters
AbbVie (NYSE:ABBV) raises FY2025 Adj EPS guidance from $10.38-$10.58 to $10.61-$10.65 vs $10.53 analyst estimate..
AbbVie (NYSE:ABBV) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.79 by 4.09 pe...
